Indications, usage and dosage of Encorafenib
Encorafenib is a targeted therapy drug mainly used for melanoma, colorectal cancer, and non-small cell lung cancer with specific gene mutations. Its dosage needs to be adjusted according to indications and adverse reactions, and special attention should be paid to medication and drug interactions in special populations.
1. Indications
Enkafenib is suitable for BRAFV600E or V600K mutation positive patients with unresectable or metastatic melanoma, colorectal cancer, and non-small cell lung cancer, and should be used in combination with other targeted drugs such as bimetinib or cetuximab.
2. Usage and dosage
(1) Standard dose
Melanoma or non-small cell lung cancer: take 450mg orally daily, in combination with bimetinib; Colorectal cancer: Take 300mg orally daily, in combination with cetuximab, and continue until disease progression or intolerable toxicity occurs.
(2) Dose adjustment
Gradually reduce according to the grading of adverse reactions: melanoma first reduced to 300mg/day, colorectal cancer first reduced to 225mg/day; If it is still intolerable, further reduction or permanent discontinuation of the medication is required.
(3) Handling of missed services
If the medication is missed and less than 12 hours have passed since the next administration, there is no need to take it again; If there is no need to supplement after vomiting, continue with the next dose according to the original plan.
3. Medication for special populations
(1) Liver and kidney dysfunction
Mild to moderate damage to liver and kidney function does not require dose adjustment; There is no clear recommended dosage for patients with severe damage, and caution should be exercised when using it.
(2) Pregnancy and lactation period
May be harmful to the fetus, prohibited during pregnancy; The safety during lactation is unknown, it is recommended to discontinue medication or stop breastfeeding.
(3) Elderly and children
Elderly patients do not need to adjust the dosage; The safety and efficacy of medication for children have not yet been established.
4. Drug interactions
When used in combination with CYP3A4 inhibitors, dosage should be reduced: potent inhibitors (such as ketoconazole) should be reduced to 150mg/day, and intermediate acting inhibitors (such as fluconazole) should be reduced to 225mg/day.
Disclaimer：《Indications, usage and dosage of Encorafenib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！